tiprankstipranks
Trending News
More News >
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
US Market

Ginkgo Bioworks Holdings (DNA) AI Stock Analysis

Compare
2,222 Followers

Top Page

DN

Ginkgo Bioworks Holdings

(NYSE:DNA)

Rating:54Neutral
Price Target:
$13.00
▲(2.69%Upside)
The overall stock score is primarily driven by financial performance challenges, with net losses and negative cash flows being significant concerns. The technical analysis shows positive momentum but is tempered by high volatility. The earnings call provides some optimism with cost reduction and strategic growth initiatives, though profitability challenges remain.
Positive Factors
Cost Savings
The company has confirmed $205M in annualized cost-savings, which represents 82% of its $250M goal, and is on track for adjusted EBITDA breakeven.
Management Transition
Steve Coen, with over 30 years of industry experience, is taking over as CFO, ensuring a smooth transition and potential stability for the company.
Revenue Growth
Ginkgo delivered 123 active revenue-generating cell programs, showing a 32% year-over-year growth, mainly driven by an increase in biopharma customers.
Negative Factors
Biotech Market Uncertainty
Biotech market uncertainty weighs on visibility and 2025 guidance, posing challenges for future revenue expectations.
Life Sciences Hesitancy
A considerable amount of 'hesitancy' in life sciences, particularly regarding outsourcing, has been noted, potentially affecting Ginkgo's growth.
Revenue per Program
Many of Ginkgo's newer programs are driving less revenue per program compared to older initiatives, which could impact overall profitability.

Ginkgo Bioworks Holdings (DNA) vs. SPDR S&P 500 ETF (SPY)

Ginkgo Bioworks Holdings Business Overview & Revenue Model

Company DescriptionGinkgo Bioworks Holdings, Inc. is a leading biotechnology company specializing in the development of custom organisms across multiple sectors, including pharmaceuticals, agriculture, food, and industrial chemicals. The company leverages its expertise in synthetic biology to design microorganisms that can produce valuable chemicals, materials, and other products. Ginkgo Bioworks operates a platform that enables the programming of cells for a variety of applications, partnering with organizations to create tailored biological solutions.
How the Company Makes MoneyGinkgo Bioworks primarily generates revenue through a combination of collaboration fees, milestone payments, and royalties from partnerships with companies across diverse industries. The company engages with partners to develop custom organisms that meet specific commercial needs, often entering into multi-year agreements that provide upfront payments and potential downstream revenue through royalties on sales of products developed using Ginkgo's engineered organisms. Additionally, Ginkgo Bioworks offers its expertise in cell programming as a service, providing access to its extensive biological engineering capabilities. Strategic collaborations and joint ventures further enhance its revenue streams, allowing the company to expand its reach and capitalize on its synthetic biology platform.

Ginkgo Bioworks Holdings Key Performance Indicators (KPIs)

Any
Any
Total Active Programs
Total Active Programs
Counts the number of ongoing projects or initiatives, indicating the company's innovation capacity and potential for future revenue streams.
Chart InsightsGinkgo Bioworks' active programs surged until late 2024, but a sharp decline followed, likely due to macroeconomic pressures and reduced demand for outsourcing R&D services. Despite this, the company is strategically expanding into new tools businesses and securing government contracts, which may offset some challenges. The earnings call highlighted significant cost reductions and improved profitability metrics, indicating a focus on financial resilience. However, ongoing net losses and a tough biotech capital market remain concerns, suggesting a cautious outlook for future program growth.
Data provided by:Main Street Data

Ginkgo Bioworks Holdings Earnings Call Summary

Earnings Call Date:May 06, 2025
(Q1-2025)
|
% Change Since: 96.28%|
Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment Neutral
The earnings call reflects significant progress in cost reduction, revenue growth in key segments, and strategic expansion into new business areas, offset by ongoing net losses and challenges in the macroeconomic environment. The sentiment is cautiously optimistic with substantial achievements but also notable challenges.
Q1-2025 Updates
Positive Updates
Significant Cost Reduction Achieved
Ginkgo Bioworks achieved a $205 million reduction in annual run rate costs between Q1 2024 and Q1 2025, exceeding the target of $200 million set for mid-2025.
Increase in Cell Engineering Revenue
Cell Engineering revenue increased by 37% to $38 million in Q1 2025 compared to Q1 2024. Excluding noncash revenue, the increase was 10%.
Strategic Expansion into Tools Business
Ginkgo Bioworks expanded its offerings to include tools business, Datapoints and Automation, aiming to diversify revenue streams and serve a broader customer base.
Improved Profitability and Cash Burn
Adjusted EBITDA improved from negative $117 million in Q1 2024 to negative $47 million in Q1 2025. Cash burn decreased from $104 million to $58 million year-over-year.
New Government Contracts
Ginkgo secured a $29 million ARPA-H contract and continues to work on 28 government projects with a significant backlog.
Negative Updates
Continued Net Loss
Despite improvements, Ginkgo Bioworks reported a net loss for Q1 2025, highlighting ongoing challenges in reaching profitability.
Macro Environment Challenges
The biotech capital market is experiencing a tough time, which presents challenges in securing funding and affects the overall industry outlook.
Pressure on Outsourcing in Biopharma
There is a general hesitancy and reduced demand for outsourcing R&D services, impacting Ginkgo's traditional solutions business.
Company Guidance
During the earnings call, Ginkgo Bioworks provided significant guidance on their financial and strategic trajectory. The company reported a $205 million reduction in their annual run rate between Q1 2024 and Q1 2025, surpassing their target of $200 million by Q3 2025, and is on track to reach adjusted EBITDA breakeven by the end of 2026. They also highlighted their strong financial position with $517 million in cash and cash equivalents and no bank debt. Revenue from the Cell Engineering business grew by 37% year-over-year to $38 million, with a 32% increase in revenue-generating programs. Biosecurity revenue was reported at $10 million for the quarter with a segment gross margin of 28%. The call also included updated full-year revenue guidance, now expected to be between $167 million and $187 million, reflecting a $7.5 million noncash deferred revenue release. Additionally, the company emphasized their strategic progress in launching new tools businesses, such as Datapoints and Automation, as well as expanding opportunities with government clients, notably securing a $29 million ARPA-H contract.

Ginkgo Bioworks Holdings Financial Statement Overview

Summary
Ginkgo Bioworks Holdings is facing substantial financial challenges with consistent net losses and negative operating cash flows. While the company maintains a reasonable leverage position and gross profit margins, the negative profitability and cash flow issues highlight the need for strategic improvements.
Income Statement
40
Negative
Ginkgo Bioworks Holdings has shown a declining trend in revenue from 2022 to TTM (Trailing-Twelve-Months) 2025. The gross profit margin for TTM 2025 is approximately 73.55%, indicating efficient cost management relative to revenue. However, the company is facing significant losses with a net profit margin of -198.86% in TTM 2025, highlighting profitability challenges. EBIT and EBITDA margins are also negative, showing operational inefficiencies.
Balance Sheet
50
Neutral
The company's balance sheet shows a moderate debt-to-equity ratio of 0.67 in TTM 2025, indicating reasonable leverage. The equity ratio stands at 50.06%, suggesting a balanced equity position. However, the return on equity is negative due to the net losses, indicating challenges in generating returns for shareholders.
Cash Flow
45
Neutral
Operating cash flow remains negative at -$281.8 million in TTM 2025, indicating cash outflows from core operations. The free cash flow to net income ratio is poor, reflecting challenges in converting earnings into cash. However, the company has shown some improvement in free cash flow since 2024, with a growth rate of 9.63%.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue237.42M227.04M251.46M477.71M313.84M76.66M
Gross Profit174.71M188.49M197.45M273.49M184.15M61.05M
EBITDA-384.69M-484.39M-821.29M-2.06B-1.81B-108.58M
Net Income-472.07M-547.03M-892.87M-2.10B-1.83B-126.61M
Balance Sheet
Total Assets1.29B1.38B1.67B2.54B2.07B675.15M
Cash, Cash Equivalents and Short-Term Investments516.92M561.57M944.07M1.32B1.55B380.80M
Total Debt434.56M467.73M241.77M442.59M23.03M17.00M
Total Liabilities646.04M661.39M568.19M803.04M503.61M205.10M
Stockholders Equity647.43M716.06M1.10B1.74B1.51B461.38M
Cash Flow
Free Cash Flow-345.30M-382.13M-336.30M-304.47M-310.34M-193.65M
Operating Cash Flow-281.85M-319.58M-295.50M-252.20M-253.82M-135.83M
Investing Cash Flow-248.81M-62.24M-80.69M-67.39M-73.26M-67.12M
Financing Cash Flow-1.10M-1.74M-3.22M95.34M1.53B90.32M

Ginkgo Bioworks Holdings Technical Analysis

Technical Analysis Sentiment
Positive
Last Price12.66
Price Trends
50DMA
8.14
Positive
100DMA
8.31
Positive
200DMA
8.77
Positive
Market Momentum
MACD
0.92
Negative
RSI
79.21
Negative
STOCH
93.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNA, the sentiment is Positive. The current price of 12.66 is above the 20-day moving average (MA) of 9.15, above the 50-day MA of 8.14, and above the 200-day MA of 8.77, indicating a bullish trend. The MACD of 0.92 indicates Negative momentum. The RSI at 79.21 is Negative, neither overbought nor oversold. The STOCH value of 93.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNA.

Ginkgo Bioworks Holdings Risk Analysis

Ginkgo Bioworks Holdings disclosed 70 risk factors in its most recent earnings report. Ginkgo Bioworks Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Ginkgo Bioworks Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$510.67M
DNDNA
54
Neutral
$741.01M-57.76%13.76%48.34%
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
45
Neutral
$406.65M-26.14%74.59%
44
Neutral
$430.67M-33.14%
34
Underperform
$410.77M-45.82%10.38%
33
Underperform
$658.62M-71.44%19.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DNA
Ginkgo Bioworks Holdings
12.66
-0.68
-5.10%
SANA
Sana Biotechnology
2.92
-2.17
-42.63%
TRML
Tourmaline Bio
16.19
3.66
29.21%
ERAS
Erasca
1.45
-0.72
-33.18%
RAPP
Rapport Therapeutics, Inc.
11.80
-12.13
-50.69%
MAZE
Maze Therapeutics, Inc.
11.86
-3.14
-20.93%

Ginkgo Bioworks Holdings Corporate Events

Executive/Board ChangesShareholder Meetings
Ginkgo Bioworks Holds Annual Shareholder Meeting, Elects Directors
Positive
Jun 13, 2025

On June 12, 2025, Ginkgo Bioworks Holdings, Inc. conducted its annual meeting of shareholders, where a significant majority of shares were represented. The meeting resulted in the election of seven directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, shareholders approved the executive compensation on an advisory basis, indicating broad support for the company’s leadership and strategic direction.

The most recent analyst rating on (DNA) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Ginkgo Bioworks Announces CFO Transition
Neutral
May 21, 2025

On May 21, 2025, Ginkgo Bioworks announced the resignation of its Chief Financial Officer, Mark Dmytruk, effective May 30, 2025, as he transitions to another organization. Steven Coen, the current Chief Accounting Officer, will assume the role of CFO, bringing over 30 years of experience in public accounting and corporate finance. Coen’s appointment is expected to provide continuity and build upon the financial strategies laid out by Dmytruk, with a focus on achieving cost reduction targets and reaching Adjusted EBITDA breakeven by the end of 2026.

The most recent analyst rating on (DNA) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025